or Try an Advanced Search...

    Morphinans Stocks List

    Symbol Grade Name % Change
    NKTR B Nektar Therapeutics 12.00
    COLL D Collegium Pharmaceutical, Inc. 0.32
    TRVI D Trevi Therapeutics, Inc. -8.24
    DRRX D DURECT Corporation -0.05
    ALKS F Alkermes plc -1.06
    INDV F Indivior PLC 0.00
    PMD F Psychemedics Corporation 0.00
    TTNP F Titan Pharmaceuticals, Inc. 0.00
    VRPX F Virpax Pharmaceuticals, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Opioids Chemical Compounds Euphoriants Organic Compounds Pain Pharmaceutical Schizophrenia Biopharmaceutical Chronic Pain Drug Delivery Drugs Ethers Hydrocodone Hyperactivity Disorder Oxycodone Phenols Analgesics Attention Deficit Hyperactivity Disorder Atypical Antipsychotics Bupivacaine

    Related ETFs - A few ETFs which own one or more of the above listed Morphinans stocks.

    Symbol Grade Name Weight
    PSCH C PowerShares S&P SmallCap Health Care Portfolio 4.58
    PSIL F AdvisorShares Psychedelics ETF 4.48
    IBRN D iShares Neuroscience and Healthcare ETF 3.61
    FBT D First Trust Amex Biotech Index Fund 3.29
    PBE C PowerShares Dynamic Biotech & Genome 3.21
    View all Morphinans ETFs...
    Compare ETFs
    Compare PSCH to PSIL Compare PSIL to FBT Compare PSIL to PBE

        Morphinans Stocks Recent News

        Date Stock Title
        May 8 TRVI Q1 2024 Trevi Therapeutics Inc Earnings Call
        May 7 TRVI Trevi Therapeutics Reports Q1 2024 Financial Results: A Detailed Analysis
        May 7 TRVI Trevi Therapeutics reports Q1 results
        May 7 DRRX DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
        May 7 TRVI Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
        May 7 COLL Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
        May 2 NKTR Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
        May 2 ALKS Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
        May 2 COLL Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
        May 2 ALKS Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
        May 1 TRVI Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
        May 1 ALKS Alkermes plc (ALKS) Q1 2024 Earnings Call Transcript
        May 1 ALKS Alkermes plc 2024 Q1 - Results - Earnings Call Presentation
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Opioids Chemical Compounds Euphoriants Organic Compounds Pain Pharmaceutical Schizophrenia Biopharmaceutical Chronic Pain Drug Delivery Drugs Ethers Hydrocodone Hyperactivity Disorder Oxycodone Phenols Analgesics Attention Deficit Hyperactivity Disorder Atypical Antipsychotics Bupivacaine
        Morphinans

        Morphinan is the prototype chemical structure of a large chemical class of psychoactive drugs, consisting of opiate analgesics, cough suppressants, and dissociative hallucinogens, among others.

        More about Morphinans
        Browse All Tags